ESR1 and breast cancer: Entinostat another HDAC inhibitor targeting HDAC1, 2, and 3 coupled with Exemestane in postmenopausal women with ER+ advanced breast cancer demonstrated good safety and promising results in the ENCORE301 randomized phase II study, with increased PFS and OS [76].